The mesenchymal stroma has been shown to play a crucial role in the development of multiple myeloma, partly by secretion of interleukin (IL)-6, that serves as a growth factor for myeloma cells. However, it is still unclear which other stromal molecules are involved in the pathogenesis of this disease. We chose, as a model system, a mouse plasmacytoma cell line, which does not respond to IL-6. We found that the formation of mouse plasmacytoma tumors, in an in vivo skin transplantation model, is facilitated by co-injection of these tumor cells along with a mesenchymal stromal cell. The tumor promoting effect of the stroma was reproduced in an in vitro model; stromal cells induced the proliferation of plasmacytoma cells under serumfree conditions. This growth promotion could not be mimicked by a series of cytokines including IL-6 and insulin-like growth factor (IGF)-I implying a role for yet unidentified stromal factors. The in vivo formation of plasmacytoma tumors was reduced following administration of activin A, a cytokine member of the transforming growth factor (TGF)␤ superfamily. Furthermore, the in vitro growth promoting effect of the stroma was abrogated by basic fibroblast growth factor (bFGF) which induced a higher stromal expression of activin A. Our results thus show that mesenchymal stroma expresses plasmacytoma growth stimulating activities that overcome the low constitutive level of the plasmacytoma inhibitor, activin A. The expression of activin A is upregulated by bFGF rendering the stroma suppressive for plasmacytoma growth. The balance between the expression of these regulators may contribute to mesenchymal stroma activity and influence the progression of multiple myeloma. Leukemia (2001) 15, 1102-1110. 
Introduction
The mesenchyme is one of the determining factors in the development, expansion and spread of malignant tumors. [1] [2] [3] The contribution of mesenchyme to the control of tumor growth is not restricted to solid tumors. Various mouse leukemia cells show in vitro growth dependence on the stroma. 4, 5 Furthermore, in the human disease, multiple myeloma, the tumor cells are attracted to the bone marrow microenvironment 6 wherein they are protected by stroma from chemotherapeutic drugs 7 and show growth dependence upon interactions with the mesenchymal stroma. [8] [9] [10] A well known survival factor for myeloma cells, and their normal counterparts, is the cytokine interleukin-6 (IL-6) (for review see Ref. 11) , which is provided by the bone marrow stromal microenvironment. 12 Cells from some multiple myeloma patients harbor an intracellular or extracellular autocrine IL-6 loop or are mutated in a way that enables their survival in the absence of IL-6. Others require exogenously supplied IL-6. [13] [14] [15] Although IL-6 is secreted from the stroma and supports multiple myeloma cell growth, additional unidentified molecules 9 have been shown to play a critical role in the process of myeloma cell dependence on stroma. Moreover, emergence of IL-6-independent clones within the tumor myeloma cell population correlates with increased malignancy of multiple myeloma. 16 Our previous studies on bone marrow-derived mesenchymal and endothelial stromal cell lines demonstrated the ability of these cells to promote the growth of human carcinoma cells in vitro, 17 a finding which is in line with the known role of stroma in tumor growth support. On the other hand, we have shown that stromal cells reduce the in vitro proliferation of several sarcoma cell lines 17 and that primary bone marrow stroma and endothelial-like stromal cell lines inhibit the proliferation of plasmacytomas, 18, 19 the mouse counterpart of human multiple myeloma. It was found that the ability of the stroma to suppress the growth of plasmacytomas is due to secretion of activin A, a cytokine member of the transforming growth factor (TGF) ␤ superfamily. [20] [21] [22] [23] This phenomenon is highly specific since other normal and tumor hemopoietic cells from different lineages were resistant to activin A. Our studies further showed that activin A kills plasmacytomas by antagonism with the survival signal of IL-6. This antagonism is overcome by surplus amount of IL-6. 20 It is likely therefore that the interplay between these two cytokines contributes to the control of normal plasma cell survival and is involved in the pathogenesis of multiple myeloma. Both IL-6 24 and activin A 25, 26 are expressed by the mesenchyme, however, stromal cell types differ dramatically in the level of secretion of activin A and accordingly some are inhibitory while others are permissive to plasmacytoma cells. 18 In the present study we show that bone marrow-derived mesenchymal stromal cells which support hemopoiesis [27] [28] [29] and are poor producers of activin A, 18 enhance plasmacytoma tumor incidence in vivo, probably by elaborating stimulating factors. This phenomenon was reproduced in an in vitro model of plasmacytoma/stroma co-culture. The in vitro experiments further revealed that basic fibroblast growth factor (bFGF) may play a role in the interactions between the mesenchymal stroma and the tumor plasmacytoma cell.
Materials and methods

Cells
The 14F1.1, MBA-15, MBA-13 stromal cell lines [27] [28] [29] [30] were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco, Grand Island, NY, USA) supplemented with 10% heat inactivated fetal calf serum (FCS) (Biolabs, Jerusalem, Israel). MPC-11 plasmacytoma cells were grown in Roswell Park Memorial Institute (RPMI)1640 (Gibco) with 10% FCS. Cell lines were incubated at 37°C in a humidified atmosphere of 10% CO 2 in air.
Transplanted tumor model
Plasmacytoma cells at 10 3 -10 5 per site were innoculated intra-dermally in 100 l of either DMEM or in the same growth medium supplemented with 1% (w/v) methylcellulose, or 5 × 10 4 or 1.25 × 10 5 14F1.1 cells, into 2-4 months old male nude CD1 outbred mice (Olac) (20 animals per experimental group). Mice were examined daily for 3 months. Tumors were first visible 17-21 days post injection, depending on the specific experiment. Tumor development was monitored in diameter measurements, and reached an average diameter of over 2 cm at the end of 2 months. Mice bearing such large tumors were killed to prevent unnecessary suffering. Local tumors and various organs were histologically examined. In all instances tumors developed at the site of injection and did not spread to other organs. Injection of the stromal cell line 14F1.1 did not yield tumors. Cells rescued from three tumors chosen randomly were propagated in vitro and showed the expected plasmacytoma phenotype.
In vitro biological assays Activin A assay:
Activin A was monitored using MPC-11 plasmacytoma cells. MPC-11 cells were seeded at 4-8 × 10 3 cells/ml in 96-well microtiter plates (100 l/well) (Costar, Cambridge, MA, USA) in RPMI supplemented with 7.5% FCS in the presence of serial dilutions of activin or buffer (20 mM Tris-HCl pH 7.8 or 20 mM Hepes pH 7.8). Cell viability was determined following 4 days of incubation using the 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric assay, which measures cell viability via mitochondrial activity. 31 One unit of activity was designated as the amount of protein which, under the above conditions, caused 50% growth inhibition relative to the control. Where indicated, in experiments of MPC-11/stroma co-culture, MPC-11 cell growth was estimated by 3 H-thymidine incorporation (Rotem Industries, Israel, 1 Ci/well) for 16 h.
Induction of MPC-11 plasmacytoma cell growth by the stroma under serum-free conditions:
14F1.1, MBA-13 and MBA-15 stromal cells were removed by trypsin, washed with DMEM, resuspended in DMEM supplemented with Biogro-1 (defined serum-free medium) and seeded in concentrations that create immediate confluence, in 100 l in Falcon 96-well microtiter plates. Following adherence of the stromal cells, MPC-11 cells were washed in DMEM, resuspended in DMEM supplemented with Biogro-1 and seeded (400 cells/well) with or without the stroma. After 4 or 5 days of incubation, cells were labeled with 3 H-thymidine (0.5 Ci/well) for 6 h, harvested and radioactivity was determined.
The effect of stroma cells conditioned medium (CM) or purified cytokines on plasmacytoma cells growth under serumfree conditions:
MPC-11 cells were washed in DMEM, resuspended in DMEM supplemented with Biogro-1 and seeded (400 cells/well) with stromal CM. After 4-5 days of incubation cell viability was determined by using the MTT colorimetric assay as described above. 32 and bFGF were kindly provided by Pharmacia Biocenter (Nerviano, Italy). IL-6 was obtained from Dr J Van Snick, Ludwig Institute for Cancer Research, Brussels. Recombinant mouse IL-1␣, IL-2, IL-4 and IL-7, ckit ligand, and recombinant human IL-10, IL-11 and PDGF were purchased from Genzyme Corporation (Boston, MA, USA). Human G-CSF was kindly provided by Dr S Gillis of Immunex Corporation (Seattle, WA, USA). Recombinant bovine activin A was purchased from Innogenetics (Belgium) or was purified in our laboratory as previously described. 20 Human flt-3 and SDF-1 were purchased from R&D Systems (Minneapolis MN, USA). 
Cytokines
RT-PCR
Total RNA from MPC-11 and 14F1.1 cells was reversetranscribed and PCR amplified. The following primers were used: ActRIIA, 5Ј-AGGCTAATGTGGTCTCTTGGA-3Ј and 5Ј-TCAAGAGATGGATGCTGGCCAA-3Ј, 33 follistatin, 5Ј-CCAA GCAAAGAACGGCCGC-3Ј and 5Ј-TTTCTCAGGTGGCA GGCGC-3Ј. 34 The expected size for ActRIIA was 440 bp and for follistatin, 560 bp.
Results
The development of localized plasmacytoma tumors is promoted by stromal cells and suppressed by activin A
In order to study the contribution of the microenvironment to plasmacytoma tumor growth we developed an assay system of a local skin plasmacytoma tumor in nude mice. The MPC-11 plasmacytoma is a clonal cell population that proliferates in vitro at a constant doubling time of 14 h, irrespective of seeding concentration. 4, 35 This cell line does not require exogenous addition of IL-6. In view of the factor-independent growth of MPC-11 cells in vitro it was expected that these cells would readily form tumors in vivo. However, inoculation into immuno-compromised mice required high cell numbers to produce high tumor incidence. On average, first tumors were visible at day 17 post injection. Low cell numbers, of 10 3 cells per site, did not result in tumor formation even 2 months after injection whereas 10 5 cells per site produced an average of about 60% tumor bearing mice (Figure 1a) . We tested whether this tumor growth deficiency could be corrected by stromal cells. A low number of plasmacytoma cells (10 3 ), that by themselves do not form tumors, injected together with the 14F1.1 stromal cells, at 5 × 10 4 per mouse, resulted in a high incidence of tumor bearing mice (Figure 1a) . The proportion of cells in the admixture of MPC-11 and the stroma appears to be of importance since a relatively higher number of stromal cells did not improve tumor take and even slightly reduced it (Figure 1b) . The stromal cell line by itself did not yield tumors in any of the 30 mice injected. Moreover, we confirmed the nature of the plasmacytoma tumors by histopathological examination and by propagating in vitro MPC-11 cells rescued from these tumors (data not shown). The question was then raised: was this effect mediated by stroma serving as a mechanical anchor for the plasmacytoma cells, preventing cell spread and elimination by phagocytosis, or whether the stroma provides growth stimulatory signals? To examine these possibilities we injected MPC-11 cells while embedded in methylcellulose (MC). In contrast to controls where 10 3 MPC-11 cells were insufficient for tumor growth, injection of the same number of cells embedded in MC produced an incidence of about 50% tumor bearing mice ( Figure  1c) . We then chose an optimal concentration of both agents and examined them separately or combined together. 14F1.1 stroma embedded in MC was more powerful than MC and stromal cells, each applied separately, in promoting plasmacytoma tumor growth. At day 23 post injection the incidence of tumors in the group obtaining both MC and stromal cells was over 40% whereas the summation of incidences with each agent alone amounts up to less than 20% (Figure 1d ). This additive effect of MC and the stroma imply that each operates through a different mechanism. Thus, the stroma may elaborate a plasmacytoma stimulating activity. However, stromal cells express activin A, 36, 37 which has been shown to cause apoptotic death of plasmacytomas and hybridomas. 21 The plasmacytoma used in the current study, MPC-11, expresses receptors for activin A (activin receptor type IIA) as evidenced by immuno-staining using a specific antibody ( Figure 2 ) and by PCR detection of corresponding mRNA transcripts ( Figure  3 ) and are accordingly sensitive to this cytokine in vitro, as we previously reported. 21 We further show here that inoculation of the plasmacytoma cells along with activin A, in vivo, caused retardation of tumor development (Figure 1e ). Although 14F1.1 cells express activin A mRNA they are relatively poor producers of functional activin A amongst the MBA Figure 2 MPC-11 plasmacytoma express activin receptor type IIA: MPC-11 cells were stained with rabbit antibodies to ActRIIA (A) and with DNA stain Hoechst (B). Original magnification ×1000.
Figure 3
RT-PCR analysis. ActRIIA mRNA in MPC-11 plasmacytoma cells and follistatin mRNA in 14F1.1 stromal cells. cell line series. 19 This is due to the fact that 14F1.1 cells express functional antagonists of activin A; RT-PCR analysis of mRNA showed expression of the activin A inhibitor follistatin (Figure 3 ). In addition, media conditioned by 14F1.1 cells interfered with the biological activity of recombinant activin A (not shown). This blocking of activin A function may allow the tumor supporting activity of the stromal cell line observed in vivo.
We next attempted to identify, in an in vitro model, the putative plasmacytoma promoting activity produced by the stroma.
bFGF renders stromal cells inhibitory to plasmacytoma by upregulation of activin A expression
Mouse MPC-11 plasmacytoma cells are capable of proliferating in fetal calf serum-supplemented medium. By contrast, these cells die when seeded in serum-replacing medium (Biogro). The inability of MPC-11 cells to grow under these conditions could be overcome by seeding on to confluent lay-
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Figure 4
Stromal cells induce the growth of MPC-11 plasmacytoma under serum-free conditions. MPC-11 cells were seeded on to confluent layers of mesenchymal stromal cells (14F1.1 adipocytes, MBA-13 fibroendothelial or MBA-15 osteoblast) in serum-free medium. Cell growth was determined by examination of ers of stromal cells (Figure 4 ). Several stromal cell lines of mesenchymal origin, including the osteogenic cell line MBA-15, the fibroendothelial cell line MBA-13 and the adipocyte cell line 14F1.1, mediated this activity. To further characterize this stromal activity we maintained confluent layers of the MBA-13 stromal cell line in serum-free medium and collected the conditioned medium (CM). This CM promoted the growth of MPC-11 plasmacytoma under serum-free conditions ( Figure  5a ). The active molecules within this CM were of an apparent size greater than 10 kDa, as indicated by their retention in the concentrate following Amicon ultrafiltration (Figure 5b ). The active factor(s) was resistant to freeze drying, was precipitated by ammonium sulfate (not shown) and was heat labile ( Figure  5c ). These results indicate that the plasmacytoma growth promoting activity is released from stromal cells under serum-free conditions and can readily be detected in the growth medium. Thus far we could not identify this stromal activity since a series of cytokines, listed in Table 1 , could not support MPC-11 cell growth. Activin A which is inhibitory to MPC-11 in serum containing media, was also tested to ensure it does not have an opposite stimulatory effect in the absence of serum. IL-3, IL-4, G-CSF and GM-CSF 29, 38 and MIP1␣ (Bilbao et al, unpublished) can also be excluded as candidate stromaderived stimulators of MPC-11 cells since they are undetectable in unstimulated 14F1.1 stroma.
We have previously shown that bFGF modulates stromal cell morphology, modifies the expression of cytokine genes and, consequently, changes the effect of the stroma on hematopoiesis; 37 preincubation of the stroma with bFGF was sufficient to modify the stromal cell capacity to support longterm hematopoiesis. 37 We therefore examined the capacity of bFGF to affect stromal support of MPC-11 cell growth. As shown in Figure 6a , addition of bFGF to co-cultures of MPC-11 cells and confluent layers of the 14F1.1 stromal cell line, abrogated the growth stimulating effect of the latter. The proliferation of MPC-11 cells in serum containing medium was Stromal cells secrete a high molecular weight, heat labile, plasmacytoma growth promoting activity. Conditioned media (CM) from MBA-13 stromal cells were prepared in DMEM supplemented with 2% Biogro, in the absence of serum. MPC-11 cells, at 800 per well, were seeded in 96-well microtiter plates under serum-free conditions and with the indicated concentration of stromal CM, and were incubated for 3 days. Viability was estimated by the MTT assay (a). The CM was further fractionated using a YM10 Amicon membrane: the retained material was concentrated 5-fold (5× concentrate) and the effect of this concentrate on growth of MPC-11 cells is compared to that of the unfractionated CM and the flow through (filtrate). An additional control is DMEM supplemented with 2% Biogro that was concentrated 10-fold (10× Biogro) to ensure that any effect seen is not resulting from concentration of the medium supplements (b). Unfractionated CM, incubated for 1 h at 42°C, lost most of its plasmacytoma promoting activity (c).
Table 1
The effect of stroma cells and purified cytokines on serum-free growth of plasmacytoma cells
Additions
MPC-11 cell growth
Stroma-CM unaffected by the addition of bFGF (Figure 6b ). This implied that the effect of bFGF on plasmacytoma cell growth is mediated through modulation of stromal functions. The question was then raised as to whether bFGF induces the expression by the stroma, of an agent inhibitory to the plasmacytoma cells. We have previously shown that bFGF causes increased expression of activin A mRNA in stromal cells. 37 To examine whether the bFGF-mediated suppression of plasmacytoma growth was related to secretion of activin A we used the natural inhibitor of activin A, follistatin. 39 Whereas recombinant activin A strongly suppressed MPC-11 cell growth, addition of follistatin abrogated the effect of activin A ( Figure  6c ). Follistatin added to bFGF-treated stromal cells reversed the inhibitory effect of bFGF in a dose-dependent manner (Figure 6a ). Follistatin itself had no direct effect on MPC-11 cell growth (Figure 6b ). It is therefore concluded that unstimulated stromal cells are permissive for plasmacytoma growth but may become inhibitory, following bFGF triggering, due to increased secretion of activin A.
Discussion
Solid tumors, like any tissues or organs, are dependent on the supportive functions of the endothelial vascular network 40 and mesenchymal stroma. [1] [2] [3] The interactions between the malignantly transformed cell and the stroma determine the potential of the tumor to grow and spread. It is likely that the molecular mechanisms that underlie the functions of the mesenchymal stroma in tumors are basically similar to the functions that the stroma mediates in normal tissues. The study of the mode by which the mesenchyme controls tumor cell growth may therefore contribute to our understanding of tumor development and may unravel mechanisms that control normal cell organization. We show in this study that long-term cultured plasmacytoma tumor cells which are apparently autonomous in culture, ie proliferate in serum-supplemented media, without the support of added growth factors, are nonetheless, responsive to stromal cell signals; the MPC-11 plasmacytoma was growth-stimulated in vitro by mesenchymal stromal cells and their ability to form in vivo-localized tumors was promoted by co-injection with stromal cells. Thus, plasmacytoma cells, like their normal counterparts, react to stromal signals and their growth is supported in vivo by mesenchymal stroma. Moreover, the promotion of the plasmacytoma tumor growth was unrelated to IL-6. These observations are relevant to specific aspects in the biology of multiple myeloma. First, myeloma cells tend to reside within the bone marrow stromal microenvironment during early stages of the disease (for review see Ref. 6) . Secondly, myeloma cells demonstrate in vitro dependence [8] [9] [10] and adhesive interactions with the stroma, which seem to be mediated through VLA-4/fibronectin and several other adhesion molecules. [41] [42] [43] [44] Thirdly, myeloma cells from a significant proportion of patients are unresponsive to IL-6 or contain a fraction of cells that do not respond to this cytokine. 45 Moreover, several cell lines derived from multiple myeloma patients are IL-6 independent. 12, 46 Finally, the emergence of IL-6-independent clones correlates with increased severity of the disease. 16 Thus, the cultured plasmacytoma cell line used in our present study demonstrates well, when injected in vivo or upon in vitro examination, both the dependence on bone marrow stroma and the independence of IL-6, which are characteristic of particular myeloma cell types or denote advanced stages in this disease.
A transplanted localized nude mouse skin tumor model was used in this study. The nude mouse has been extensively used in studies on skin tumors. 47, 48 This model allows a macroscopic follow-up, by simple physical examination, of the developing tumors. It is demonstrated here that the rules that apply to solid tumors also hold for the hematopoietic tissuederived plasmacytoma cells, the mouse equivalent of human multiple myeloma. Although the skin tumors that occurred following co-injection of plasmacytoma cells and stroma reached several gram sizes within 2 months, and animals were then killed to minimize suffering, no invasion into internal organs was observed upon histopathological examination. We verified the nature of the tumors by rescuing plasmacytoma cells from several tumors and propagating them in vitro (results not shown). This simple experimental procedure may be used to examine the efficacy of the use of anti-tumor agents as demonstrated here by the effect of activin A application (Figure 1e) .
To examine the contribution of the stroma to tumor development in vivo we chose the 14F1.1 stroma, since this cell line is contact inhibited in vitro and does not form tumors in vivo. Part of the effect of this cell line on tumor incidence may be 'mechanical' in providing an extracellular matrix anchor that immobilizes the tumor cells to the site of inoculation. Indeed, MC, which is an inert viscous material, also promoted tumor growth. However, the stroma and MC, Leukemia applied together, had an additive effect on tumor incidence indicating that the stroma provides additional factors, possibly growth promoting cytokines. This conclusion is strongly supported by the in vitro study showing that stromal cells release plasmacytoma growth stimulating activity under serum-free conditions. In contrast, MPC-11 cells seeded in vitro under these conditions in MC, failed to proliferate (not shown). Thus, the in vivo effect of MC is probably to anchor the cells to the injection site.
The nature of the stromal activity that promotes the growth of the MPC-11 plasmacytoma in vivo is unknown. The in vitro reproduction of this phenomenon, ie the effect of the stroma on serum-free growth of the plasmacytoma, may represent only part of the in vivo effect. Whereas in vivo the stroma may contribute to vascularization, extracellular matrix deposition or other solid tumor organization parameters, the in vitro effect is limited to growth promotion. An evident candidate was IL-6, however, MPC-11 cells are independent of exogenously supplemented IL-6. Moreover, IL-6 and a long list of cytokines shown in Tab1e 1, had no effect on plasmacytoma cell growth under serum-free conditions. Although we have tested various combinations of these cytokines it is not practically possible to cover all possibilities. Therefore, it cannot be excluded that the stromal activity is in fact a combination of several known cytokines. A previous report 9 suggested that the MM5.1 multiple myeloma cell line is dependent on stroma due to a combined action of IL-6 and an additional undefined stromal activity. It is evident that a host of mesenchymal regulatory molecules are yet to be identified. Some clue as to the nature of stroma-derived regulatory molecules is indicated by the study of hematopoiesis which implicated several cytokines, chemokines, adhesion molecules and extracellular matrix components. 49, 50 Whether these molecules account for hemopoietic stem cell maintenance and other stromal cell functions, remains a matter of debate. Cytokine combinations have been used in vitro to obtain long-term proliferation of human cord blood cells with an early phenotype, capable of SCID/NOD mouse repopulation. 51 However, a similar culture system is not sufficient to maintain stem cells from other sources. Several lines of evidence point to a possible major role of TGF␤ superfamily members in the regulation of hemopoietic cell growth and differentiation. 52 In Xenopus, activin and bone morphogenic protein (BMP)-4 operate along with bFGF in the induction of erythropoiesis. 53 Similarly, the killer effect of activin A on tumor plasma cells 21 and its differentiation inducing effects on erythroleukemias [54] [55] [56] are well established. Thus, the molecular basis for the various mesenchymal stroma functions, including the subject matter of this study, stromal regulation of tumor growth, still remains to be elucidated. bFGF contributes to tumor development through its angiogenic functions. 57 This, however, is but one facet of its plieotropic activities. bFGF affects hematopoiesis indirectly by modulating stromal cell functions. Pre-treatment of stroma with bFGF caused increased long-term production of hematopoietic cells. 37 However, conflicting data have been published pointing to negative modulation of hematopoiesis by bFGFtreated stroma. 58 In the present study we show that bFGF operates through induction of activin A expression to render the stroma suppressive to plasmacytoma cells. The 14F1.1 cell constitutively expresses low levels of activin A and does not therefore interfere with plasmacytoma cell proliferation, whereas bFGF modifies this cell line to become restrictive to plasmacytomas. It is therefore possible that within the bone marrow microenvironment, as well as at any mesenchymal site, bFGF may control the degree of activin A expression. Consequently, a high local concentration of bFGF would reduce the incidence of plasma-like cells at the site. However, bFGF and its receptors have been reported to critically contribute to tumor development 59, 60 and have recently been implicated in the induction of multiple myeloma cell growth. bFGF operates in promotion of multiple myeloma by induction of angiogenesis and by directly increasing myeloma cell proliferation. 61, 62 This cytokine seems, therefore, to positively affect myeloma cell growth by a direct effect while it also has an indirect effect which is growth suppressive and stroma mediated. The balance between these opposing activities may determine the development of plasma cell tumors within the bone marrow microenvironment. It remains to be examined whether stromal cells of multiple myeloma patients are less responsive to bFGF, in terms of secretion of activin A, and consequently more permissive for myeloma cell proliferation.
To date, conventional therapy of multiple myeloma results in a median survival of 4 years and most patients eventually succumb. 63, 64 Better understanding of the pathology of this disease may provide new modalities for treatment. In view of the observed dependence of myeloma and plasmacytoma cells on mesenchyme, further studies on the mechanism of this cell interaction may provide a clue to the molecular basis of this disease.
